Immunotherapy biotech BeneVir Biopharm raises $2 million

The company is moving toward commercialization of its virus technology that can infect and kill cancer cells while evading the immune system.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.